Plasma Protein Therapeutics Market Size & Growth Forecast 2026–2035, By Segments (Product, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Plasma Protein Therapeutics Market size was around USD 32.89 Billion in 2025 and is slated to grow at a 6.2% CAGR from 2026 to 2035, surpassing USD 60.02 Billion by 2035. The industry revenue for 2026 is estimated at USD 34.66 billion.
Get more details on this report
Request Free Sample ReportPlasma Protein Therapeutics Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific accounted for 37.84% of the market in 2025, supported by a large patient base, expanding treatment access, improving healthcare infrastructure, and consistent hospital use of plasma-derived therapies.
- Europe is projected to grow at a 7.01% CAGR, driven by structured treatment pathways, strong adoption of plasma-derived therapies, mature reimbursement systems, and continued demand for immunoglobulin-based treatments.
Segment Momentum
- Immunoglobulin held a 52.82% share in 2025 due to its essential role in long-term immune replacement and immune modulation, supporting consistent demand across established treatment pathways.
- Hemophilia is the fastest-growing application as improving diagnosis and treatment access increase demand for plasma-derived therapies used in reliable bleeding management and factor replacement.
Market Expansion Drivers
- Growing prevalence of age-related and chronic diseases driving demand for plasma-based therapies.
- Increasing approvals and clinical research in immunoglobulin and albumin therapies expanding treatment scope.
- Advancements in subcutaneous immunoglobulin delivery improving patient accessibility and treatment adherence.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the plasma protein therapeutics market include CSL Behring LLC (Australia), Grifols S.A. (Spain), Octapharma AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Baxter International Inc. (United States), Kedrion S.p.A. (Italy), Bio Products Laboratory Ltd. (United Kingdom), Biotest AG (Germany), LFB Group (France), Sanofi S.A. (France).Regional and Segment Outlook
Asia PacificMarket Growth Drivers and Industry Trends
As patient populations age and long-duration conditions become more common, prescribing patterns increasingly favor therapies that can address immune deficiencies, bleeding disorders, neurological conditions, and critical care needs over repeated treatment cycles. In the plasma protein therapeutics market, this expands the treated pool not only through new diagnoses but also through sustained utilization, since many plasma-derived products such as immunoglobulins, coagulation factors, and albumin are used in ongoing disease management rather than one-time intervention. Demand is reinforced by the clinical reality that older and chronically ill patients often present with complex comorbidities, making established plasma-based therapies a practical choice in hospital, specialty infusion, and home-care settings.
Increasing approvals and clinical research in immunoglobulin and albumin therapies expanding treatment scope
A broader approval base and active clinical research pipeline are reshaping treatment algorithms by moving immunoglobulin and albumin therapies into a wider set of indications and care settings. For the plasma protein therapeutics market, each regulatory approval does more than add a label expansion; it gives physicians stronger reimbursement support, clearer prescribing confidence, and a more standardized route to adoption in routine practice. Ongoing research also sharpens product differentiation around formulation, dosing, and disease targeting, which influences procurement decisions by providers and encourages manufacturers to invest in capacity, portfolio expansion, and lifecycle management tied to high-value therapeutic segments.
Advancements in subcutaneous immunoglobulin delivery improving patient accessibility and treatment adherence
Improvements in subcutaneous immunoglobulin administration are changing how treatment is delivered, shifting a portion of care away from infusion centers toward home-based and self-administered use. In the plasma protein therapeutics market, that practical change increases market penetration by reducing logistical barriers such as travel, chair time, and scheduling constraints that often limit long-term therapy continuity. Better tolerability profiles, easier training for self-infusion, and more flexible dosing routines also influence market adoption by helping clinicians place suitable patients on maintenance therapy earlier and keep them on treatment more consistently, which strengthens recurring demand for immunoglobulin products.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing demand for plasma protein therapeutics | 2.10% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Expansion of biopharmaceutical production and distribution | 2.00% | Medium term (2–5 yrs) | Europe, Asia Pacific | Medium | Moderate |
| Technological advancements in plasma fractionation and purification | 2.10% | Long term (5+ yrs) | North America, Asia Pacific | Medium | Moderate |
| Growing prevalence of age-related and chronic diseases driving demand for plasma-based therapies | 2.00% | High | North America, Europe | High | Near Term |
| Increasing approvals and clinical research in immunoglobulin and albumin therapies expanding treatment scope | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Advancements in subcutaneous immunoglobulin delivery improving patient accessibility and treatment adherence | 1.60% | High | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Asia Pacific held a 37.84% share of the plasma protein therapeutics market in 2025, supported by its large patient base, expanding treatment access, and broad use of plasma-derived therapies across major healthcare systems. The region’s leadership is aided by rising diagnosis and management of immunological, hematological, and critical care conditions that rely on albumin, immunoglobulins, and coagulation factors in routine hospital practice. Demand is also underpinned by improving healthcare infrastructure and procurement capacity, which helps move these therapies more consistently from specialist centers into wider clinical use.
Europe is projected to expand at a 7.01% CAGR over the forecast period, with growth in the plasma protein therapeutics market being fueled by steady therapeutic adoption and a well-established clinical framework for plasma-derived products. The region benefits from structured treatment pathways, strong utilization in chronic and rare disease management, and continued demand for immunoglobulin-based therapies in specialist care settings. Growth is further supported by the practical reality that mature reimbursement and hospital distribution systems can accelerate uptake when patient identification and long-term treatment continuity improve.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Fractionation ExcellenceGermany focuses on advanced plasma fractionation capabilities and stringent manufacturing standards for plasma protein therapeutics. Companies in Germany invest in production efficiency, quality assurance, and long-term plasma sourcing to support consistent therapeutic availability.
France 🇫🇷
Therapeutic Access StrategyFrance prioritizes plasma protein therapeutics that improve treatment accessibility for chronic and rare conditions. Healthcare stakeholders in France support efficient plasma collection, optimized distribution, and evidence-based adoption across specialized treatment centers.
Italy 🇮🇹
Plasma Collection ExpansionItaly is reinforcing plasma protein therapeutics by improving domestic plasma collection and strengthening processing capacity. Clinical institutions in Italy focus on maintaining reliable therapeutic availability while supporting high standards for plasma-derived medicinal products.
Japan 🇯🇵
Rare Disease SupportJapan continues strengthening plasma protein therapeutics for immune deficiencies and rare diseases through specialized healthcare delivery. Manufacturers in Japan emphasize product safety, traceability, and dependable domestic supply to meet evolving clinical requirements.
South Korea 🇰🇷
Biopharma Manufacturing FocusSouth Korea is expanding plasma protein therapeutics through investments in biopharmaceutical manufacturing and advanced processing capabilities. Healthcare organizations in South Korea seek high-quality plasma-derived therapies supported by modern production infrastructure and regulatory compliance.
United States 🇺🇸
Advanced Biologics PipelineThe U.S. plasma protein therapeutics market emphasizes expanding plasma collection networks and developing therapies for immunological and rare disorders. Healthcare providers in the U.S. prioritize reliable supply chains and innovative plasma-derived products to address growing clinical demand.
Segment Leadership and Growth Trends
Plasma Protein Therapeutics Market Share (%), Product, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportImmunoglobulin held the strongest position in the plasma protein therapeutics market in 2025, accounting for a 52.82% share. its position is underpinned by its central role in long-term immune replacement and immune modulation, which supports steady utilization across established treatment pathways. Demand in the plasma protein therapeutics market remains anchored by the clinical necessity of immunoglobulin in managing chronic and recurrent immune-related conditions, giving this product segment a durable consumption base that alternatives do not match as broadly.
Albumin is emerging as the fastest-growing product segment in the plasma protein therapeutics market because its use is closely tied to critical care, volume restoration, and hospital-based treatment settings where demand expands with broader acute care needs. Growth momentum is being reinforced by its practical utility across multiple intervention scenarios, allowing albumin to gain traction faster than more narrowly used plasma-derived products. This wider applicability in frontline clinical management is a key reason the segment is accelerating relative to alternatives.
Application Segment Analysis: Primary Immunodeficiency Disorder (PIDD) (Largest Segment) vs Hemophilia (Fastest-Growing Segment)
Primary Immunodeficiency Disorder (PIDD) represented the largest application in the plasma protein therapeutics market in 2025, with a 28.62% share. This position is supported by the ongoing need for repeated and structured therapy in patients requiring continuous immune support, which creates a stable treatment volume over time. Within the plasma protein therapeutics market, PIDD maintains leadership because care delivery is often long term rather than episodic, reinforcing consistent product demand through established clinical management patterns.
Hemophilia is the fastest-growing application segment in the plasma protein therapeutics market, influenced by the sustained need for plasma-derived therapies in bleeding management where reliable factor replacement remains essential. Its growth is gaining momentum as treatment access and diagnosis improve in settings where plasma-based therapeutic options continue to play a practical role in care delivery. Compared with more stable application areas, hemophilia is expanding faster because therapy demand is closely linked to broader treatment adoption and increasing clinical reach.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Albumin, Immunoglobulin, Plasma-derived Factor VIII, Others | Immunoglobulin | Albumin |
| Application | Hemophilia, Primary Immunodeficiency Disorder (PIDD), Idiopathic Thrombocytopenic Purpura (ITP), Others | Primary Immunodeficiency Disorder (PIDD) | Hemophilia |
Competitive Landscape and Market Positioning
1. CSL Behring LLC (Australia)
2. Grifols S.A. (Spain)
3. Octapharma AG (Switzerland)
4. Takeda Pharmaceutical Company Limited (Japan)
5. Baxter International Inc. (United States)
6. Kedrion S.p.A. (Italy)
7. Bio Products Laboratory Ltd. (United Kingdom)
8. Biotest AG (Germany)
9. LFB Group (France)
10. Sanofi S.A. (France)
Advancements in biologics and rare disease therapies are accelerating innovation in the plasma protein therapeutics market. In the plasma protein therapeutics market, improved fractionation methods and targeted therapies are expanding treatment possibilities for complex conditions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Prime Medicine | May-25 | Prime Medicine advanced a preclinical Alpha-1 Antitrypsin Deficiency program using Prime Editing technology, targeting an IND/CTA filing in 2026. The development strengthens its gene-editing pipeline in plasma protein disorder therapeutics, reflecting continued innovation in next-generation biologics for rare disease treatment. |
| KRRO | Apr-25 | KRRO-110 received orphan-drug designation for Alpha-1 Antitrypsin Deficiency treatment, supporting accelerated development and regulatory incentives. The designation enhances KRRO’s position in rare plasma protein disorder therapeutics and improves its pathway toward clinical advancement and potential commercialization. |
| CSL | Feb-25 | CSL divested its Wuhan plasma assets to Chengdu Rongsheng for USD 185 million, reflecting strategic portfolio optimization within its plasma operations. The transaction supports resource reallocation across CSL’s broader plasma-derived therapies business and streamlines its global manufacturing and asset footprint. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Plasma Protein Therapeutics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Plasma Protein Therapeutics Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much is the plasma protein therapeutics market worth?
What is the expected industry size of plasma protein therapeutics by 2035?
How is the growing prevalence of chronic and age-related diseases influencing long-term demand for plasma protein therapies?
What is driving the expansion of subcutaneous immunoglobulin delivery in improving treatment accessibility?
Why does Immunoglobulin lead the plasma protein therapeutics market?
Which application is expanding the fastest in the plasma protein therapeutics market?
Why does Asia Pacific lead the plasma protein therapeutics market?
What is driving the rapid growth of the plasma protein therapeutics market in Europe?
What are the key competitors in the plasma protein therapeutics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization